Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von PapaSmurf 

Exelixis Inc. diskutieren

Exelixis Inc.

WKN: 936718 / Symbol: EXEL / Name: Exelixis / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /

23,95 €
0,42 %

Einschätzung Buy
Rendite (%) 18,21 %
Kursziel 25,26
Veränderung
Endet am 01.05.25

Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at TD Cowen from $25.00 to $27.00. They now have a "buy" rating on the stock.
Ratings data for EXEL provided by MarketBeat

Einschätzung Buy
Rendite (%) 18,98 %
Kursziel 26,01
Veränderung
Endet am 03.05.25

Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.
Ratings data for EXEL provided by MarketBeat

Exelixis, Inc. (NASDAQ: EXEL) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for EXEL provided by MarketBeat

Exelixis, Inc. (NASDAQ: EXEL) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for EXEL provided by MarketBeat

Einschätzung Buy
Rendite (%) 11,29 %
Kursziel 26,80
Veränderung
Endet am 30.07.25

Exelixis, Inc. (NASDAQ: EXEL) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $29.00 price target on the stock.
Ratings data for EXEL provided by MarketBeat

Einschätzung Buy
Rendite (%) -1,92 %
Kursziel 24,72
Veränderung
Endet am 07.08.25

Exelixis, Inc. (NASDAQ: EXEL) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $27.00 price target on the stock.
Ratings data for EXEL provided by MarketBeat

Einschätzung Buy
Rendite (%) -2,52 %
Kursziel 30,28
Veränderung
Endet am 08.08.25

Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $33.00 price target on the stock, up previously from $32.00.
Ratings data for EXEL provided by MarketBeat

Einschätzung Buy
Rendite (%) 0,25 %
Kursziel 26,07
Veränderung
Endet am 18.09.25

Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock.
Ratings data for EXEL provided by MarketBeat

Einschätzung Buy
Rendite (%) 1,59 %
Kursziel 24,17
Veränderung
Endet am 26.09.25

Exelixis, Inc. (NASDAQ: EXEL) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $27.00 price target on the stock.
Ratings data for EXEL provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 27,36
Veränderung
Endet am 04.10.25

Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Royal Bank of Canada from $27.00 to $30.00. They now have an "outperform" rating on the stock.
Ratings data for EXEL provided by MarketBeat